Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 14/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812138 | 0.83 | ALDH1A1 (0.51) | KDM4EALDH1A1SMN1; SMN2TSHRKMT2A | |
| SCHEMBL19706279 | 0.83 | SMN1; SMN2 (0.54) | KDM4EALDH1A1EPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL19706280 | 0.83 | SMN1; SMN2 (0.54) | KDM4EALDH1A1EPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL19707136 | 0.83 | SMN1; SMN2 (0.54) | KDM4EALDH1A1EPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL24220688 | 0.83 | SMN1; SMN2 (0.54) | KDM4EALDH1A1EPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL17369089 | 0.79 | CYP3A4 (0.54) | KDM4EALDH1A1RAB9AHPGDNPC1 | |
| SCHEMBL8131223 | 0.78 | ALDH1A1 (0.54) | EPHX1KDM4EALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3038961 | 0.77 | ALDH1A1 (0.51) | KDM4EALDH1A1SMN1; SMN2TSHRKMT2A | |
| SCHEMBL811127 | 0.75 | CA12 (0.52) | KDM4EALDH1A1SMN1; SMN2TSHRKMT2A | |
| SCHEMBL3053595 | 0.75 | TP53 (0.57) | MAPTTP53TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| EP-2146968-B1 | UREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2015-09-23 | — | — | EP | disclosed |
| WO-2008128986-A1 | UREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | PROBIODRUG AG (DE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262063-A1 | Compounds of formula (I), combinations and uses thereof for disease therapy,** Image-1or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: | MAPT, SLC10A1, REN | EPHX1 2438/4885KDM4E 4666/4885ALDH1A1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.